{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:33:09Z","timestamp":1793835189713,"version":"4.6.1"},"reference-count":148,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T00:00:00Z","timestamp":1784073600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institutet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119777","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:06:08Z","timestamp":1784250368000},"page":"119777","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Natural compounds as epigenetic modulators in gynaecological cancers: From chemoresistance to precision oncology"],"prefix":"10.1016","volume":"202","author":[{"given":"Prakash","family":"Lingasamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blessy","family":"Kiruba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhosh","family":"Rajakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8044-6874","authenticated-orcid":false,"given":"Suhas Manikant","family":"Surisetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6473-9224","authenticated-orcid":false,"given":"Naisarg","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajitha","family":"Lulu S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-8160","authenticated-orcid":false,"given":"Andres","family":"Salumets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijayachitra","family":"Modhukur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119777_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2026.119777_bib2","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2214-109X(19)30482-6","article-title":"Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis","volume":"8","author":"Arbyn","year":"2020","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.biopha.2026.119777_bib3","article-title":"Endometrial cancer","volume":"7","author":"Makker","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2026.119777_bib4","first-page":"280","article-title":"Epithelial ovarian cancer: Evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"2019","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2026.119777_bib5","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13048-026-02115-9","article-title":"Chemoresistance in gynecologic cancers: mechanistic insights and emerging platforms to overcome drug failure","volume":"19","author":"Garg","year":"2026","journal-title":"J. Ovarian Res."},{"key":"10.1016\/j.biopha.2026.119777_bib6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cell.2012.06.013","article-title":"Cancer epigenetics: From mechanism to therapy","volume":"150","author":"Dawson","year":"2012","journal-title":"Cell"},{"issue":"6127","key":"10.1016\/j.biopha.2026.119777_bib7","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1126\/science.1230184","article-title":"Epigenetic reprogramming in cancer","volume":"339","author":"Suv\u00e0","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119777_bib8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13148-025-01917-w","article-title":"BRCA1 promoter methylation predicts PARPi response in ovarian cancer: insights from the KOMET study","volume":"17","author":"Nougarede","year":"2025","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.biopha.2026.119777_bib9","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1158\/1078-0432.CCR-22-0713","article-title":"Microsatellite instability-high endometrial cancers with MLH1 promoter hypermethylation have distinct molecular and clinical profiles","volume":"28","author":"Manning-Geist","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119777_bib10","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/ijms27020803","article-title":"HPV-Driven Cervical Carcinogenesis: Genetic and Epigenetic Mechanisms and Diagnostic Approaches","volume":"27","author":"Legaki","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119777_bib11","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1039\/b801558a","article-title":"Chemopreventive effects of natural dietary compounds on cancer development","volume":"37","author":"Pan","year":"2008","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.biopha.2026.119777_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2012.11.002","article-title":"Epigenetic Modifications by Dietary Phytochemicals: Implications for Personalized Nutrition","volume":"138","author":"Shankar","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2026.119777_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2019.00079","article-title":"Dietary compounds as epigenetic modulating agents in cancer","volume":"10","author":"Carlos-Reyes","year":"2019","journal-title":"Front. Genet."},{"key":"10.1016\/j.biopha.2026.119777_bib14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1042\/EBC20190037","article-title":"The DNA methylation landscape in cancer","volume":"63","author":"Skvortsova","year":"2019","journal-title":"Essays Biochem."},{"key":"10.1016\/j.biopha.2026.119777_bib15","doi-asserted-by":"crossref","first-page":"816","DOI":"10.3390\/cancers13040816","article-title":"Histone Modifying Enzymes in Gynaecological Cancers","volume":"13","author":"Ramarao-Milne","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119777_bib16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13046-025-03509-1","article-title":"Epigenetic regulation in gynecological cancers: a paradigm shift in immunotherapy strategies","volume":"44","author":"Zhao","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119777_bib17","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrg816","article-title":"The fundamental role of epigenetic events in cancer","volume":"3","author":"Jones","year":"2002","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.biopha.2026.119777_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/npp.2012.112","article-title":"DNA methylation and its basic function","volume":"38","author":"Moore","year":"2013","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"10.1016\/j.biopha.2026.119777_bib19","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/s41580-019-0159-6","article-title":"The diverse roles of DNA methylation in mammalian development and disease","volume":"20","author":"Greenberg","year":"2019","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119777_bib20","first-page":"40","article-title":"DNA methylation and cancer: transcriptional regulation, prognostic, and therapeutic perspective","volume":"40","author":"Bhootra","year":"2023","journal-title":"Med. Oncol. 2023"},{"issue":"1","key":"10.1016\/j.biopha.2026.119777_bib21","first-page":"52","article-title":"Versatile functions of methyl-CpG-binding domain 2 (MBD2) in cellular characteristics and differentiation","volume":"52","author":"Lekesiz","year":"2025","journal-title":"Mol. Biol. Rep. 2025"},{"key":"10.1016\/j.biopha.2026.119777_bib22","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/cas.70078","article-title":"BRCA1 Promoter Methylation in Ovarian Cancer: Clinical Relevance and a Novel Diagnostic Approach Using Fragment Analysis","volume":"116","author":"Tsuchimochi","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2026.119777_bib23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ccr.2011.07.003","article-title":"Dominantly Inherited Constitutional Epigenetic Silencing of MLH1 in a Cancer-Affected Family Is Linked to a Single Nucleotide Variant within the 5\u2019UTR","volume":"20","author":"Hitchins","year":"2011","journal-title":"Cancer Cell."},{"key":"10.1016\/j.biopha.2026.119777_bib24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ygyno.2017.06.017","article-title":"Potential of RASSF1A promoter methylation as biomarker for endometrial cancer: A systematic review and meta-analysis","volume":"146","author":"Pabalan","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"6765","key":"10.1016\/j.biopha.2026.119777_bib25","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/47412","article-title":"The language of covalent histone modifications","volume":"403","author":"Strahl","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119777_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2014.09.037","article-title":"SnapShot: Histone modifications","volume":"159","author":"Huang","year":"2014","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.biopha.2026.119777_bib27","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/nrg.2016.59","article-title":"The molecular hallmarks of epigenetic control","volume":"17","author":"Allis","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.biopha.2026.119777_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrg.2016.138","article-title":"From profiles to function in epigenomics","volume":"18","author":"Stricker","year":"2016","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.biopha.2026.119777_bib29","article-title":"Mechanisms of HDACs in cancer development","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2026.119777_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1459572","article-title":"Recombinant adenoviruses expressing HPV16\/18 E7 upregulate the HDAC6 and DNMT3B genes in C33A cells","volume":"14","author":"Shao","year":"2024","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119777_bib31","first-page":"10","article-title":"Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer","author":"Moufarrij","year":"2020","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119777_bib32","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41598-017-03362-z","article-title":"EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion","volume":"7","author":"Yi","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119777_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156232","article-title":"Non-coding RNA methylation modifications in ovarian cancer","volume":"275","author":"Deng","year":"2025","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.biopha.2026.119777_bib34","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.650554","article-title":"Exploration of the Role of m6 A RNA Methylation Regulators in Malignant Progression and Clinical Prognosis of Ovarian Cancer","volume":"12","author":"Wei","year":"2021","journal-title":"Front. Genet."},{"key":"10.1016\/j.biopha.2026.119777_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1366223","article-title":"Emerging role of m6A modification in ovarian cancer: progression, drug resistance, and therapeutic prospects","volume":"14","author":"Alam","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.biopha.2026.119777_bib36","doi-asserted-by":"crossref","first-page":"18453","DOI":"10.18632\/aging.103811","article-title":"A newly defined risk signature, consisting of three m6A RNA methylation regulators, predicts the prognosis of ovarian cancer","volume":"12","author":"Fan","year":"2020","journal-title":"Aging"},{"key":"10.1016\/j.biopha.2026.119777_bib37","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/15476286.2024.2408707","article-title":"m6A modification of RNA in cervical cancer: role and clinical perspectives","volume":"21","author":"Gao","year":"2024","journal-title":"RNA Biol."},{"key":"10.1016\/j.biopha.2026.119777_bib38","article-title":"Emerging Roles of m6A RNA Methylation Regulators in Gynecological Cancer","volume":"12","author":"Huang","year":"2022","journal-title":"Front. Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2026.119777_bib39","first-page":"14","article-title":"The roles of m6A methylation in cervical cancer: functions, molecular mechanisms, and clinical applications","author":"Mao","year":"2023","journal-title":"Cell. Death & Dis."},{"key":"10.1016\/j.biopha.2026.119777_bib40","doi-asserted-by":"crossref","DOI":"10.1186\/s40001-025-03481-8","article-title":"Research progress on m6A RNA methylation modification in human reproduction related diseases","volume":"30","author":"Sui","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.biopha.2026.119777_bib41","doi-asserted-by":"crossref","first-page":"16287","DOI":"10.18632\/aging.203157","article-title":"Immune Infiltration-Related N6-methyladenosine RNA Methylation Regulators Influence the Malignancy and Prognosis of Endometrial Cancer","volume":"13","author":"Ma","year":"2021","journal-title":"Aging"},{"key":"10.1016\/j.biopha.2026.119777_bib42","first-page":"737","article-title":"The Role of N6-Methyladenosine Methylation in the Progression of Endometrial Cancer","volume":"37","author":"Song","year":"2022","journal-title":"Cancer Biother. Radiopharm."},{"key":"10.1016\/j.biopha.2026.119777_bib43","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23942","article-title":"Effects of m6A RNA methylation regulators on endometrial cancer","volume":"35","author":"Zhang","year":"2021","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.biopha.2026.119777_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1247309","article-title":"Shining a spotlight on m6A and the vital role of RNA modification in endometrial cancer: a review","volume":"14","author":"Jin","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.biopha.2026.119777_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154630","article-title":"MicroRNA-21 in gynecological cancers: From molecular pathogenesis to clinical significance","volume":"248","author":"Jiang","year":"2023","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.biopha.2026.119777_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2017.05.011","article-title":"MicroRNAs in gynecological cancers: Small molecules with big implications","volume":"407","author":"Srivastava","year":"2017","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biopha.2026.119777_bib47","first-page":"16","article-title":"Dysregulated expression of long noncoding RNAs in gynecologic cancers","author":"Hosseini","year":"2017","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2026.119777_bib48","doi-asserted-by":"crossref","first-page":"352","DOI":"10.2174\/0113816128284380240123071409","article-title":"Interplay between LncRNA\/miRNA and TGF-\u03b2 Signaling in the Tumorigenesis of Gynecological Cancer","volume":"30","author":"Safavi","year":"2024","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2026.119777_bib49","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ygyno.2021.03.020","article-title":"Non-coding RNAs related to angiogenesis in gynecological cancer","volume":"161","author":"Rahimian","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2026.119777_bib50","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.ygyno.2021.02.004","article-title":"Exosomal microRNAs and exosomal long non-coding RNAs in gynecologic cancers","volume":"161","author":"Hashemipour","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2026.119777_bib51","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/diagnostics15050601","article-title":"A Rapid and Reliable Test for BRCA1 Promoter Hypermethylation in Paraffin Tissue Using Pyrosequencing","volume":"15","author":"Bacares","year":"2025","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.biopha.2026.119777_bib52","first-page":"16","article-title":"BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine","volume":"16","author":"Panagopoulou","year":"2024","journal-title":"Clin. Epigenetics 2024"},{"key":"10.1016\/j.biopha.2026.119777_bib53","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.23758","article-title":"Clinical significance of promoter hypermethylation of genes in ovarian cancer","author":"Zhu","year":"2017","journal-title":"Oncotarget 5"},{"key":"10.1016\/j.biopha.2026.119777_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.216706","article-title":"EZH2-mediated development of therapeutic resistance in cancer","volume":"586","author":"Kaur","year":"2024","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.biopha.2026.119777_bib55","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-023-01786-y","article-title":"EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer","volume":"22","author":"Chen","year":"2023","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2026.119777_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118106","article-title":"Recent update on the development of EZH2 inhibitors and degraders for cancer therapy","volume":"299","author":"Tang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119777_bib57","first-page":"9","article-title":"The EZH2-H3K27me3 axis modulates aberrant transcription and apoptosis in cyclophosphamide-induced ovarian granulosa cell injury","author":"Chen","year":"2023","journal-title":"Cell. Death Discov."},{"key":"10.1016\/j.biopha.2026.119777_bib58","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241306026","article-title":"Exploring oncogenic roles and clinical significance of EZH2: focus on non-canonical activities","volume":"17","author":"Wozniak","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.biopha.2026.119777_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0307178","article-title":"Overexpression of miR-200s inhibits proliferation and invasion while increasing apoptosis in murine ovarian cancer cells","volume":"19","author":"Carter","year":"2024","journal-title":"PLoS. One"},{"key":"10.1016\/j.biopha.2026.119777_bib60","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1361601","article-title":"Current strategies for early epithelial ovarian cancer detection using miRNA as a potential tool","volume":"11","author":"Bhadra","year":"2024","journal-title":"Front. Mol. Biosci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119777_bib61","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-77068-0","article-title":"Characterization of miR-200 family members as blood biomarkers for human and laying hen ovarian cancer","volume":"10","author":"Choi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119777_bib62","first-page":"41","article-title":"IL-6 regulates epithelial ovarian cancer EMT, invasion, and metastasis by modulating Let-7c and miR-200c through the STAT3\/HIF-1\u03b1 pathway","volume":"6","author":"Guo","year":"2024","journal-title":"Med. Oncol."},{"key":"10.1016\/j.biopha.2026.119777_bib63","doi-asserted-by":"crossref","first-page":"66629","DOI":"10.18632\/oncotarget.18343","article-title":"The miR200 family in ovarian cancer","volume":"8","author":"Koutsaki","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119777_bib64","doi-asserted-by":"crossref","DOI":"10.3791\/68653","article-title":"Regulation of Epithelial-Mesenchymal Transition in Ovarian Cancer by LncRNA MALAT1 via SNAI2 and MiR-200c-3p","author":"Xu","year":"2025","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.biopha.2026.119777_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2025.1633283","article-title":"Human papillomavirus-mediated cervical cancer: epigenetic interplay and clinical implications","volume":"16","author":"Sisodiya","year":"2025","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.biopha.2026.119777_bib66","doi-asserted-by":"crossref","first-page":"23930","DOI":"10.18632\/oncotarget.4525","article-title":"E6 and E7 gene silencing results in decreased methylation of tumor suppressor genes and induces phenotype transformation of human cervical carcinoma cell lines","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119777_bib67","first-page":"2655","article-title":"Crosstalk between histone modification and DNA methylation orchestrates the epigenetic regulation of the costimulatory factors, Tim-3 and galectin-9, in cervical cancer","volume":"42","author":"Zhang","year":"2019","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2026.119777_bib68","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.7150\/jca.101881","article-title":"Activation of the CCL22\/CCR4 causing EMT process remodeling under EZH2-mediated epigenetic regulation in cervical carcinoma","volume":"15","author":"Zhang","year":"2024","journal-title":"J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119777_bib69","first-page":"16","article-title":"The role and diagnostic value of deregulated miRNAs in cervical cancer","author":"Parvizi","year":"2025","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.biopha.2026.119777_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2024.108280","article-title":"Identification and validation of miR-21 key genes in cervical cancer through an integrated bioinformatics approach","volume":"113","author":"Mitra","year":"2024","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119777_bib71","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.3390\/cancers15215188","article-title":"MLH1 Methylation Testing as an Integral Component of Universal Endometrial Cancer Screening\u2014A Critical Appraisal","volume":"15","author":"Plotkin","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119777_bib72","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.3892\/or.2013.2752","article-title":"Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer","volume":"30","author":"Fiolka","year":"2013","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2026.119777_bib73","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1080\/15257770.2024.2356744","article-title":"Promoter methylation status of RASSF1A and RASSF2A tumor suppressor genes in endometrial endometrioid carcinomas","volume":"43","author":"Atmaca","year":"2024","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.biopha.2026.119777_bib74","doi-asserted-by":"crossref","DOI":"10.1177\/15330338241242637","article-title":"Endometrial Cancer Detection by DNA Methylation Analysis in Cervical Papanicolaou Brush Samples","volume":"23","author":"Wang","year":"2024","journal-title":"Technol. Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.biopha.2026.119777_bib75","first-page":"15","article-title":"miR-200a-3p promotes the malignancy of endometrial carcinoma through negative regulation of epithelial-mesenchymal transition","author":"Ma","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.biopha.2026.119777_bib76","doi-asserted-by":"crossref","first-page":"694","DOI":"10.31083\/ph.2017.7649","article-title":"MiR-200a promotes epithelial-mesenchymal transition of endometrial cancer cells by negatively regulating FOXA2 expression","volume":"72","author":"Shi","year":"2017","journal-title":"Pharmazie"},{"key":"10.1016\/j.biopha.2026.119777_bib77","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.apjtm.2017.05.007","article-title":"MiR-200a and miR-200b target PTEN to regulate the endometrial cancer cell growth in vitro","volume":"10","author":"Wu","year":"2017","journal-title":"Asian Pac. J. Trop. Med."},{"key":"10.1016\/j.biopha.2026.119777_bib78","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.3390\/ijms20236011","article-title":"Interplay between miRNAs and Genes Associated with Cell Proliferation in Endometrial Cancer","volume":"20","author":"Hermyt","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119777_bib79","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.3390\/biomedicines13112820","article-title":"Epigenetics in Ovarian Cancer: A Review of Current Knowledge and Future Perspectives","volume":"13","author":"Dedes","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119777_bib80","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","article-title":"Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses","volume":"162","author":"Chiappinelli","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2026.119777_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188894","article-title":"Advances in epigenetic modifications and cervical cancer research","volume":"1878","author":"Liu","year":"2023","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119777_bib82","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41420-024-01898-4","article-title":"Histone lactylation promotes malignant progression by facilitating USP39 expression to target PI3K\/AKT\/HIF-1\u03b1 signal pathway in endometrial carcinoma","volume":"10","author":"Wei","year":"2024","journal-title":"Cell. Death Discov."},{"key":"10.1016\/j.biopha.2026.119777_bib83","doi-asserted-by":"crossref","DOI":"10.1186\/s12957-025-04099-0","article-title":"Emerging role of histone and non-histone lactylation in metabolic reprogramming of female-specific malignancies","volume":"24","author":"Sun","year":"2025","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.biopha.2026.119777_bib84","doi-asserted-by":"crossref","first-page":"335","DOI":"10.3746\/pnf.2022.27.4.335","article-title":"A New Frontier in Studying Dietary Phytochemicals in Cancer and in Health: Metabolic and Epigenetic Reprogramming","volume":"27","author":"Shannar","year":"2022","journal-title":"Prev. Nutr. Food Sci."},{"key":"10.1016\/j.biopha.2026.119777_bib85","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2174\/1389202917666160803165229","article-title":"Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression","volume":"18","author":"Ratovitski","year":"2017","journal-title":"Curr. Genom."},{"key":"10.1016\/j.biopha.2026.119777_bib86","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.semcancer.2016.04.002","article-title":"Dietary phytochemicals as epigenetic modifiers in cancer: Promise and challenges","volume":"40\u201341","author":"Shankar","year":"2016","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.biopha.2026.119777_bib87","first-page":"7563","article-title":"Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines","volume":"63","author":"Fang","year":"2003","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119777_bib88","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/1476-4598-10-68","article-title":"Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3\/SMRT corepressor complex dissociation\/reassembly","volume":"10","author":"Rajendran","year":"2011","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.biopha.2026.119777_bib89","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.7314\/APJCP.2014.15.3.1403","article-title":"Reversal of resistance towards cisplatin by curcumin in cervical cancer cells","volume":"15","author":"Roy","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.biopha.2026.119777_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110546","article-title":"Targeting miRNAs by natural products: A new way for cancer therapy","volume":"130","author":"Zhang","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.biopha.2026.119777_bib91","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/848710","article-title":"Modulation of MicroRNAs by Phytochemicals in Cancer: Underlying Mechanisms and Translational Significance","volume":"2015","author":"Srivastava","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.biopha.2026.119777_bib92","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00280-017-3238-4","article-title":"Curcumin suppresses cisplatin resistance development partly via modulating extracellular vesicle-mediated transfer of MEG3 and miR-214 in ovarian cancer","volume":"79","author":"Zhang","year":"2017","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119777_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122224","article-title":"Curcumin modulates cell type-specific miRNA networks to induce cytotoxicity in ovarian cancer cells","volume":"334","author":"Ravindran","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2026.119777_bib94","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s13046-018-0898-9","article-title":"Regulation of PTEN expression by noncoding RNAs","volume":"37","author":"Li","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119777_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112061","article-title":"Sulforaphane enhances the cisplatin sensitivity through regulating DNA repair and accumulation of intracellular cisplatin in ovarian cancer cells","volume":"393","author":"Gong","year":"2020","journal-title":"Exp. Cell. Res."},{"key":"10.1016\/j.biopha.2026.119777_bib96","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s12935-021-01832-z","article-title":"Curcumin anti-tumor effects on endometrial cancer with focus on its molecular targets","volume":"21","author":"Jahanbakhshi","year":"2021","journal-title":"Cancer Cell. Int."},{"key":"10.1016\/j.biopha.2026.119777_bib97","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1014933","article-title":"Curcumin enhances the anti-cancer efficacy of paclitaxel in ovarian cancer by regulating the miR-9-5p\/BRCA1 axis","volume":"13","author":"Liu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119777_bib98","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2014.00028","article-title":"Enhancement of Cisplatin Sensitivity in Human Cervical Cancer: Epigallocatechin-3-Gallate","volume":"1","author":"Kilic","year":"2015","journal-title":"Front. Nutr."},{"key":"10.1016\/j.biopha.2026.119777_bib99","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2174\/1871520614666141226124110","article-title":"Berberine Exhibits Antitumor Effects in Human Ovarian Cancer Cells","volume":"15","author":"Jin","year":"2015","journal-title":"Anticancer. Agents Med. Chem."},{"key":"10.1016\/j.biopha.2026.119777_bib100","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd2060","article-title":"Therapeutic potential of resveratrol: the in vivo evidence","volume":"5","author":"Baur","year":"2006","journal-title":"Nat. Rev. Drug. Discov."},{"key":"10.1016\/j.biopha.2026.119777_bib101","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1002\/ptr.6155","article-title":"Anticancer potential of quercetin: A comprehensive review","volume":"32","author":"Rauf","year":"2018","journal-title":"Phytother. Res."},{"key":"10.1016\/j.biopha.2026.119777_bib102","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1158\/1055-9965.EPI-09-0698","article-title":"Diindolylmethane Inhibits Cervical Dysplasia, Alters Estrogen Metabolism and Enhances Immune Response in The K14-HPV16 Transgenic Mouse Model","volume":"18","author":"Sepkovic","year":"2009","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.biopha.2026.119777_bib103","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/carcin\/22.11.1809","article-title":"Cytostatic effects of 3,3\u2019-diindolylmethane in human endometrial cancer cells result from an estrogen receptor-mediated increase in transforming growth factor-alpha expression","volume":"22","author":"Leong","year":"2001","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.biopha.2026.119777_bib104","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/bs.acr.2024.05.005","article-title":"Anti-cancer activity of capsaicin and its analogs in gynecological cancers","volume":"164","author":"Brown","year":"2024","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.biopha.2026.119777_bib105","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.3390\/nu16234196","article-title":"Butyrate as a Potential Modulator in Gynecological Disease Progression","volume":"16","author":"Kim","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.biopha.2026.119777_bib106","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.semcancer.2020.06.014","article-title":"Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives","volume":"80","author":"Khatoon","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.biopha.2026.119777_bib107","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119777_bib108","article-title":"The Emerging Roles and Therapeutic Implications of Epigenetic Modifications in Ovarian Cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.biopha.2026.119777_bib109","article-title":"Cancer Chemoprevention: A Strategic Approach Using Phytochemicals","volume":"12","author":"Shankar","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119777_bib110","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.3390\/molecules28031022","article-title":"Exploration of the Use of Natural Compounds in Combination with Chemotherapy Drugs for Tumor Treatment","volume":"28","author":"Wu","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119777_bib111","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.21873\/anticanres.17362","article-title":"\u00d6. Ti\u0307mi\u0307rci\u0307-Kahraman, Effects of Curcumin and Its Analogue Desmethoxycurcumin on miR-133b and Its Target Gene GSTP-1 in Cisplatin-resistant Ovarian Cancer Cells","volume":"44","author":"\u00dclker","year":"2024","journal-title":"Anticancer. Res."},{"key":"10.1016\/j.biopha.2026.119777_bib112","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.3390\/cancers6031769","article-title":"Drug Resistance in Cancer: An Overview","volume":"6","author":"Housman","year":"2014","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119777_bib113","first-page":"479","article-title":"Efficacy and Toxicity of Low-Dose versus Conventional-Dose Chemotherapy for Malignant Tumors: a Meta-Analysis of 6 Randomized Controlled Trials","volume":"18","author":"Xie","year":"2017","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.biopha.2026.119777_bib114","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09519","article-title":"Synergistic effects of natural compounds and conventional chemotherapeutic agents: recent insights for the development of cancer treatment strategies","volume":"8","author":"Casta\u00f1eda","year":"2022","journal-title":"Heliyon"},{"issue":"1","key":"10.1016\/j.biopha.2026.119777_bib115","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119777_bib116","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2026.119777_bib117","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/advances\/nmx009","article-title":"Butyrate: A Double-Edged Sword for Health?","volume":"9","author":"Liu","year":"2018","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.biopha.2026.119777_bib118","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3390\/molecules26030752","article-title":"Potential of Sulforaphane as a Natural Immune System Enhancer: A Review","volume":"26","author":"Mahn","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.biopha.2026.119777_bib119","doi-asserted-by":"crossref","DOI":"10.1007\/s00432-024-05819-x","article-title":"Niraparib enhances antitumor immunity and contributes to the efficacy of PD-L1 blockade in cervical cancer","volume":"150","author":"Chang","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.biopha.2026.119777_bib120","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1021\/mp700113r","article-title":"Bioavailability of Curcumin: Problems and Promises","volume":"4","author":"Anand","year":"2007","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119777_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2025.1746959","article-title":"Therapeutic potential of epigallocatechin gallate in gynecologic cancer, endometriosis, polycystic ovary syndrome: a mechanistic and translational perspective","volume":"12","author":"Sanlier","year":"2026","journal-title":"Front. Nutr."},{"key":"10.1016\/j.biopha.2026.119777_bib122","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/1541-4337.12342","article-title":"Bioavailability of Quercetin in Humans with a Focus on Interindividual Variation","volume":"17","author":"Almeida","year":"2018","journal-title":"Compr. Rev. Food Sci. Food Saf."},{"key":"10.1016\/j.biopha.2026.119777_bib123","doi-asserted-by":"crossref","first-page":"66680","DOI":"10.18632\/oncotarget.19164","article-title":"Nanoformulations of curcumin: an emerging paradigm for improved remedial application","volume":"8","author":"Gera","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119777_bib124","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/5794350","article-title":"Natural Products for Cancer Therapy: A Review of Their Mechanism of Actions and Toxicity in the Past Decade","volume":"2022","author":"Ali Abdalla","year":"2022","journal-title":"J. Trop. Med."},{"key":"10.1016\/j.biopha.2026.119777_bib125","doi-asserted-by":"crossref","first-page":"14964","DOI":"10.3390\/ijms241914964","article-title":"Epigenetic Modulators as Therapeutic Agents in Cancer","volume":"24","author":"Patnaik","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119777_bib126","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1056\/NEJMra072067","article-title":"Epigenetics in Cancer","volume":"358","author":"Esteller","year":"2008","journal-title":"New. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119777_bib127","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.oraloncology.2010.01.009","article-title":"Potential role of HDAC inhibitors in cancer therapy: Insights into oral squamous cell carcinoma","volume":"46","author":"Iglesias-Linares","year":"2010","journal-title":"Oral. Oncol."},{"key":"10.1016\/j.biopha.2026.119777_bib128","first-page":"612","article-title":"Molecular signals of epigenetic states","volume":"330","author":"Bonasio","year":"2010","journal-title":"Science (1979)"},{"key":"10.1016\/j.biopha.2026.119777_bib129","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.phrs.2009.01.017","article-title":"Natural compounds for cancer treatment and prevention","volume":"59","author":"Nobili","year":"2009","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2026.119777_bib130","article-title":"Advancing herbal medicine: enhancing product quality and safety through robust quality control practices","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2026.119777_bib131","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1021\/acs.jnatprod.9b00949","article-title":"Scientific and Regulatory Approach to Botanical Drug Development: A U.S. FDA Perspective","volume":"83","author":"Wu","year":"2020","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.biopha.2026.119777_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2019.119373","article-title":"Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery","volume":"219","author":"Lingasamy","year":"2019","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.biopha.2026.119777_bib133","doi-asserted-by":"crossref","first-page":"29369","DOI":"10.1038\/s41598-025-11299-x","article-title":"Targeting oncofetal fibronectin and neuropilin-1 in solid tumors with PL2 peptide","volume":"15","author":"Lingasamy","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119777_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmt.2025.100119","article-title":"Multi-omics advances in understanding cancer drug resistance","volume":"12","author":"Liu","year":"2025","journal-title":"Biomed. Technol."},{"key":"10.1016\/j.biopha.2026.119777_bib135","doi-asserted-by":"crossref","first-page":"3993","DOI":"10.1016\/j.csbj.2025.08.038","article-title":"OncoProExp: An interactive shiny web application for comprehensive cancer proteomics and phosphoproteomics analysis","volume":"27","author":"Rahmani","year":"2025","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.biopha.2026.119777_bib136","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-017-0500-7","article-title":"The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer","volume":"9","author":"Widschwendter","year":"2017","journal-title":"Genome Med."},{"key":"10.1016\/j.biopha.2026.119777_bib137","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.csbj.2025.12.018","article-title":"Explainable machine learning for preoperative relapse prediction in molecularly stratified endometrial cancer: A single-center finnish cohort study","volume":"31","author":"Vela Moreno","year":"2026","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.biopha.2026.119777_bib138","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2217\/epi-2017-0118","article-title":"MethSurv: A Web Tool to Perform Multivariable Survival Analysis Using DNA Methylation Data","volume":"10","author":"Modhukur","year":"2018","journal-title":"Epigenomics"},{"key":"10.1016\/j.biopha.2026.119777_bib139","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ncrna.2023.10.006","article-title":"ExplORRNet: An interactive web tool to explore stage-wise miRNA expression profiles and their interactions with mRNA and lncRNA in human breast and gynecological cancers","volume":"9","author":"Lawarde","year":"2024","journal-title":"Noncoding RNA Res."},{"key":"10.1016\/j.biopha.2026.119777_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15476286.2025.2577433","article-title":"Serum-MiR-CanPred: deep learning framework for pan-cancer classification and miRNA-targeted drug discovery","volume":"22","author":"Patel","year":"2025","journal-title":"RNA Biol."},{"key":"10.1016\/j.biopha.2026.119777_bib141","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.3390\/ijms22094435","article-title":"Deep Learning in Virtual Screening: Recent Applications and Developments","volume":"22","author":"Kimber","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119777_bib142","doi-asserted-by":"crossref","DOI":"10.3390\/biom12030367","article-title":"The Role of Epigenetic Modifications in Human Cancers and the Use of Natural Compounds as Epidrugs: Mechanistic Pathways and Pharmacodynamic Actions","volume":"12","author":"Bouyahya","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.biopha.2026.119777_bib143","article-title":"Artificial Intelligence in cancer epigenomics: a review on advances in pan-cancer detection and precision medicine","volume":"18","author":"Sahoo","year":"2025","journal-title":"Epigenetics Chromatin"},{"key":"10.1016\/j.biopha.2026.119777_bib144","doi-asserted-by":"crossref","DOI":"10.1093\/biomethods\/bpae028","article-title":"Early detection and diagnosis of cancer with interpretable machine learning to uncover cancer-specific DNA methylation patterns","volume":"9","author":"Newsham","year":"2024","journal-title":"Biol. Methods Protoc."},{"key":"10.1016\/j.biopha.2026.119777_bib145","article-title":"MBMethPred: a computational framework for the accurate classification of childhood medulloblastoma subgroups using data integration and AI-based approaches","volume":"14","author":"Rahmani","year":"2023","journal-title":"Front. Genet."},{"key":"10.1016\/j.biopha.2026.119777_bib146","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1158\/1535-7163.MCT-06-0087","article-title":"Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin","volume":"5","author":"Chearwae","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2026.119777_bib147","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11010-006-9302-8","article-title":"Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin","volume":"296","author":"Limtrakul","year":"2007","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.biopha.2026.119777_bib148","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s11095-008-9735-8","article-title":"Curcumin inhibits the activity of ABCG2\/BCRP1, a multidrug resistance-linked ABC drug transporter in mice","volume":"26","author":"Shukla","year":"2009","journal-title":"Pharm. Res."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226008139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:47:50Z","timestamp":1787179670000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226008139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":148,"alternative-id":["S0753332226008139"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119777","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Natural compounds as epigenetic modulators in gynaecological cancers: From chemoresistance to precision oncology","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119777"}}